Aurinia Pharmaceuticals Inc.
AUPH
$8.18
$0.080.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 235.13M | 220.36M | 207.11M | 191.41M | 175.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 235.13M | 220.36M | 207.11M | 191.41M | 175.51M |
| Cost of Revenue | 49.03M | 51.00M | 62.29M | 63.51M | 63.79M |
| Gross Profit | 186.10M | 169.36M | 144.82M | 127.89M | 111.72M |
| SG&A Expenses | 172.03M | 185.07M | 190.46M | 192.61M | 195.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.55M | 3.33M | 1.40M | -1.94M | 2.48M |
| Total Operating Expenses | 222.61M | 239.40M | 254.15M | 254.18M | 261.30M |
| Operating Income | 12.52M | -19.04M | -47.05M | -62.78M | -85.79M |
| Income Before Tax | 7.45M | -20.14M | -48.10M | -61.71M | -77.47M |
| Income Tax Expenses | 1.70M | 2.41M | 2.25M | 854.00K | 551.00K |
| Earnings from Continuing Operations | 5.75 | -22.55 | -50.35 | -62.56 | -78.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.75M | -22.55M | -50.35M | -62.56M | -78.02M |
| EBIT | 12.52M | -19.04M | -47.05M | -62.78M | -85.79M |
| EBITDA | 31.96M | 495.00K | -27.15M | -47.00M | -74.14M |
| EPS Basic | 0.04 | -0.16 | -0.35 | -0.44 | -0.55 |
| Normalized Basic EPS | 0.13 | -0.05 | -0.18 | -0.24 | -0.34 |
| EPS Diluted | 0.04 | -0.16 | -0.35 | -0.44 | -0.55 |
| Normalized Diluted EPS | 0.13 | -0.06 | -0.18 | -0.24 | -0.34 |
| Average Basic Shares Outstanding | 572.57M | 573.32M | 573.11M | 572.56M | 571.19M |
| Average Diluted Shares Outstanding | 581.45M | 576.70M | 573.90M | 572.56M | 571.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |